137 results match your criteria xerosis developed

Study of antimicrobial activity of Unani poly herbal toothpaste "".

Heliyon 2021 Feb 24;7(2):e06249. Epub 2021 Feb 24.

Department of Ilmul Advia (Pharmacology), Faculty of Unani Medicine, India.

Objective: The present study was envisioned to develop a traditional Unani toothpowder into toothpaste form along with its physicochemical standardization and evaluation of anti microbial activity against oral pathogens by study.

Materials And Methods: Herbal extracts based powder was redesigned to toothpaste as per the Pharmacopoeial guidelines and its pharmaceutical evaluation was conceded as per the Indian Government Tooth Paste Specifications. In vitro study was done to evaluate the antibacterial activity by using agar well diffusion method against dental pathogens. Read More

View Article and Full-Text PDF
February 2021

Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents--An Observational Clinical Study.

Clin Breast Cancer 2021 Jan 23. Epub 2021 Jan 23.

Department of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India.

Background: Systemic chemotherapy and targeted agents are associated with various cutaneous toxicities. Even though cutaneous toxicities are manageable, it often results in treatment discontinuation and worsens the patients' quality of life.

Aim: The study aimed to determine the spectrum of cutaneous toxicities in patients receiving systemic chemotherapy and targeted agents for breast cancer patients. Read More

View Article and Full-Text PDF
January 2021

Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.

Dermatology 2021 Jan 28:1-5. Epub 2021 Jan 28.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Background: Epidermal growth factor receptor (EGFR) inhibitors are routinely used in advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, their use is associated with gastrointestinal and cutaneous toxicities, including acneiform eruptions, pruritus, xerosis, nail and hair changes. Aside from reducing patients' quality of life, such cutaneous reactions have a considerable impact on the oncologic treatment given that dose reduction or even drug discontinuation may be necessary, especially for the severe forms. Read More

View Article and Full-Text PDF
January 2021

Treatment practices in the management of scabies in infants younger than two months.

Pediatr Dermatol 2021 Mar 24;38(2):431-435. Epub 2021 Jan 24.

Department of Dermatology, University of California, San Francisco, CA, USA.

Background/objectives: Efficacy and safety data of scabies treatments in infants are limited. Although topical permethrin is used in the treatment of scabies in adults, it is not approved for use in infants younger than 2 months of age in many parts of the world. This study aimed to describe treatment practices in the management of scabies in infants younger than 2 months. Read More

View Article and Full-Text PDF

Pool Toes: Case Report and Review of Pool-Associated Pedal Dermatoses.

Philip R Cohen

Cureus 2020 Nov 28;12(11):e11756. Epub 2020 Nov 28.

Dermatology, San Diego Family Dermatology, National City, USA.

Pool swimmers are susceptible to pedal dermatoses. The causes for these conditions are asteototic dermatitis, contact dermatitis, friction-induced injury, infections, keratoderma, pruritus, thermal injury, ultraviolet radiation exposure, and urticaria. The specific dermatoses include aquagenic keratoderma, aquagenic pruritus, aquagenic urticaria, cold-induced urticaria, contact urticaria, erosion interdigitalis blastomycetica, erythrasma, Mycobacterium abscessus hand and foot disease, onychomycosis, photosensitivity, pitted keratolysis, plantar verruca, pool dermatitis, pool feet, pool toes, pool water dermatitis, pseudomonas hot-foot syndrome, skin cancer, subcorneal hematoma, sunburn, swim fin dermatitis, tinea pedis, toe web infection, and xerosis. Read More

View Article and Full-Text PDF
November 2020

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.

PLoS One 2020 21;15(12):e0243997. Epub 2020 Dec 21.

Institut Sainte-Catherine, Avignon, France.

Background: Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemotherapy, a standard-of-care first-line treatment regimen for patients with KRAS wt mCRC.

Patients And Methods: PREMIUM is a prospective, French multicenter, observational study that recruited patients with KRAS wt mCRC scheduled to receive cetuximab, with or without first-line chemotherapy, as part of routine clinical practice, between October 28, 2009 and April 5, 2012 (ClinicalTrials. Read More

View Article and Full-Text PDF
February 2021

Cutaneous manifestations in pediatric oncology patients.

Pediatr Dermatol 2021 Jan 12;38(1):58-65. Epub 2020 Nov 12.

Dermatology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.

Background/objectives: Oncology patients present with various skin manifestations related to primary disease and treatments. Although these skin toxicities are well described in adults, studies of pediatric oncology patients are limited. The objective of this study was to evaluate the cutaneous findings in pediatric oncology patients receiving chemotherapy. Read More

View Article and Full-Text PDF
January 2021

Dermatologic manifestations in pediatric patients after liver and HSCT: A 20-year retrospective cohort study.

Pediatr Transplant 2021 May 3;25(3):e13916. Epub 2020 Nov 3.

Division of Dermatology, Department of Pediatrics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.

LT and HSCT are now potentially curative treatments for many medical conditions. Dermatologic manifestations are one of the sequelae after transplantation. To study the prevalence and associated risk factors of dermatologic manifestations after pediatric LT and HSCT. Read More

View Article and Full-Text PDF

Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration.

J Oncol Pharm Pract 2020 Nov 2:1078155220970621. Epub 2020 Nov 2.

Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerahpasa, Istanbul, Turkey.

Introduction: Novel anti-cancer drugs such as targeted cancer therapies and immune check-point inhibitors (ICIs) have adverse events, especially concerning the skin. The aim of this study is to report an overview of the commonly consulted dermatological side effects of ICIs and targeted cancer therapies in clinical practice, along with their management.

Methods: In this single-center study, we evaluated consecutive oncological patients who were referred from the oncology outpatient clinic to the dermatology outpatient clinic due to skin side effects of ICIs and targeted therapies. Read More

View Article and Full-Text PDF
November 2020

Modeling the Dose Response Relationship of Waterborne Acanthamoeba.

Risk Anal 2021 Jan 13;41(1):79-91. Epub 2020 Oct 13.

Department of Biosystems and Agricultural Engineering, Michigan State University, East Lansing, MI, USA.

This study developed dose response models for determining the probability of eye or central nervous system infections from previously conducted studies using different strains of Acanthamoeba spp. The data were a result of animal experiments using mice and rats exposed corneally and intranasally to the pathogens. The corneal inoculations of Acanthamoeba isolate Ac 118 included varied amounts of Corynebacterium xerosis and were best fit by the exponential model. Read More

View Article and Full-Text PDF
January 2021

Dermatological side effects of targeted antineoplastic therapies: a prospective study.

Cutan Ocul Toxicol 2020 Dec 20;39(4):380-384. Epub 2020 Oct 20.

Oncology Department, Haseki Training and Research Hospital, Istanbul, Turkey.

Introduction: Epidermal growth factor receptor inhibitors (EGFRs) are chemotherapeutic agents used in multiple solid organ malignity. These medications have common dermatological side effects, particularly papulopustular (PPL) lesions. The management of the diagnosis and treatment processes for such side effects may facilitate the continuation of chemotherapy and enhance the patient's quality of life. Read More

View Article and Full-Text PDF
December 2020

Nevoid melanoma and eruptive nevi from erlotinib.

Dermatol Online J 2020 Jun 15;26(6). Epub 2020 Jun 15.

Department of Dermatology, University of California San Diego, San Diego, CA.

Cutaneous side effects such as acneiform eruption, xerosis, and paronychia are frequently observed in patients undergoing treatment with epidermal growth factor receptor (EGFR) inhibitors for non-small cell lung cancer and other solid tumors. Interestingly, these side effects appear to positively correlate with length of remission, indicating that disruption of homeostatic EGFR signaling in the skin may serve as a marker of therapeutic EGFR inhibition in tumors. We report the case of a woman with metastatic lung cancer in remission being treated with the EGFR inhibitor, erlotinib, who experienced numerous commonly occurring adverse cutaneous reactions early in her treatment, and after two years of treatment developed eruptive nevi as well as a nevoid melanoma. Read More

View Article and Full-Text PDF

Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience.

Clin Colorectal Cancer 2020 12 29;19(4):e235-e242. Epub 2020 May 29.

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Introduction: Medical treatment of advanced colorectal cancer is effective in prolonging the survival of patients. The aim of this study was to describe the most common skin toxicities that occur in those patients, analyzing the association between the type of reaction and the different chemotherapeutic drugs; and to evaluate the importance of an outpatient dermatologic service to improve quality of life.

Patients And Methods: Seventy-two patients with skin reactions from advanced colorectal cancer chemotherapy were included. Read More

View Article and Full-Text PDF
December 2020

Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.

Medicine (Baltimore) 2020 Jun;99(23):e20510

School of Nursing, College of Medicine, Chang Gung University.

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is the primary treatment option for patients with non-small cell lung cancer (NSCLC). However, one of the major adverse effects associated with this therapy is skin toxicity, which impacts the patient's quality of life. This study aimed to describe the severities and locations of skin toxicity, and to analyze their association with the quality of life in patients with advanced NSCLC who received EGFR-TKI therapy as first-line treatment. Read More

View Article and Full-Text PDF

Diabetic Skin Changes Can Benefit from Moisturizer and Cleanser Use: A Review

J Drugs Dermatol 2019 Dec;18(12):1211-1217

INTRODUCTION: Diabetes mellitus (DM) associated skin changes, which may be the first sign of DM in undiagnosed patients. Frequently these patients present with dry skin, which may benefit from the use of gentle cleansers and moisturizers. A review paper was developed to explore DM-associated skin changes and possible benefits of cleanser and moisturizer use. Read More

View Article and Full-Text PDF
December 2019

Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.

Pediatr Transplant 2020 02 15;24(1):e13626. Epub 2019 Dec 15.

Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

TBC regimens are considered as "reduced toxicity" and are increasingly employed in pediatric HSCT. In our center, we commonly use the combination of treosulfan-thiotepa-fludarabine and ATG for pediatric non-malignant diseases. As we often observe acute skin toxicities following this conditioning regimen, we conducted a prospective observational study to describe and characterize these toxicities. Read More

View Article and Full-Text PDF
February 2020

Efficacy and Safety of Alitretinoin Therapy in Korean Elderly Patients with Chronic Hand Eczema: A Retrospective Single Center Study.

Ann Dermatol 2019 Dec 31;31(6):595-600. Epub 2019 Oct 31.

Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea.

Background: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clinical trials have found that alitretinoin is an effective and well-tolerated treatment for CHE. However, there is a relative lack of data on the effectiveness of alitretinoin in elderly patients. Read More

View Article and Full-Text PDF
December 2019

Diagnosis and treatment of xerosis cutis - a position paper.

J Dtsch Dermatol Ges 2019 11;17 Suppl 7:3-33

Department of Dermatology, University Medical Center, Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany.

Background And Rationale: Xerosis cutis (also referred to as xeroderma, dry skin, asteatosis) affects more than 10 million individuals in Germany. It is among the most common dermatological diagnoses and a cardinal symptom of many dermatological, internal and neurological diseases. Even though it has been established that basic skin care plays a significant role in the management of patients with xerosis cutis, there are as yet no evidence-based algorithms for diagnosis and treatment. Read More

View Article and Full-Text PDF
November 2019

Grover's Disease in a Kidney Transplant Recipient.

Acta Dermatovenerol Croat 2019 Sep;27(3):192-194

Professor Nikolina Bašić-Jukić, MD, PhD, Department of Nephrology, Arterial , Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Kišpaticeva 12, 10000 Zagreb, Croatia;

Dear Editor, It is not unusual for patients with renal insufficiency to develop skin pathologies. There are reports in the literature of increased incidence of calciphylaxis, pruritus, perforating dermatoses, and porphyria cutanea tarda in this patient population (1). Although it is quite rare, Grover's disease (GD) has been reported in several patients with renal insufficiency, but only once in a renal transplant recipient (2). Read More

View Article and Full-Text PDF
September 2019

Pruritus in patients with chronic leg ulcers: A frequent and often neglected problem.

Int Wound J 2019 Dec 2;16(6):1464-1470. Epub 2019 Sep 2.

Department of Dermatology, Venereology and Allergology, University Hospital of Essen, Germany.

There is a paucity of studies regarding pruritus in patients with chronic leg ulcers. Data were collected using newly developed questionnaires for patients and physicians to evaluate pruritus in individuals with chronic leg ulcers. The results show that a total of 50 patients with chronic leg ulcers were included in this prospective study. Read More

View Article and Full-Text PDF
December 2019

Atopic Dermatitis-Like Rash During Evolocumab Treatment of Familial Hypercholesterolemia.

J Nippon Med Sch 2019 ;86(3):187-190

Department of Endocrinology, Nippon Medical School Chiba Hokusoh Hospital.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that targets the low-density lipoprotein (LDL) receptor for lysosomal degradation. PCSK9 impedes the receptor-mediated clearance of LDL-cholesterol, thereby increasing serum LDL-cholesterol levels. Evolocumab, a human monoclonal antibody against PCSK9, effectively reduces serum LDL-cholesterol levels. Read More

View Article and Full-Text PDF
December 2019

Presence and characteristics of among Danish elderly living in nursing homes.

Future Sci OA 2019 Jun 24;5(6):FSO399. Epub 2019 Jun 24.

Department of Health Science & Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.

Aim: To explore the pattern of occurrence and characteristics of among elderly living in nursing homes in the Northern region of Denmark.

Materials & Methods: A Danish questionnaire was developed and distributed to six nursing homes from which 46 residents participated.

Results: The prevalence of chronic itch was 28. Read More

View Article and Full-Text PDF

Conceptual Model to Illustrate the Symptom Experience and Humanistic Burden Associated With Atopic Dermatitis in Adults and Adolescents.

Dermatitis 2019 Jul/Aug;30(4):247-254

LEO Pharma A/S, Ballerup, Denmark.

Atopic dermatitis (AD) is a pruritic or painful dermatologic disease characterized by xerosis and eczema lesions. The symptoms/signs of AD can significantly impact patients' health-related quality of life (HRQoL). This study aimed to qualitatively explore the adult and adolescent experience of AD. Read More

View Article and Full-Text PDF
January 2020

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis.

Dermatol Ther (Heidelb) 2019 Sep 29;9(3):407-420. Epub 2019 Jun 29.

Department of Dermatology, University of California, San Francisco, CA, USA.

Introduction: Atopic dermatitis (AD) is an inflammatory skin disease with a chronic, relapsing course. Clinical features of AD vary by age, duration, and severity but can include papules, vesicles, erythema, exudate, xerosis, scaling, and lichenification. However, the most defining and universal symptom of AD is pruritus. Read More

View Article and Full-Text PDF
September 2019

Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases.

Indian Dermatol Online J 2019 May-Jun;10(3):251-255

Department of Dermatology, MLN Medical College Allahabad, Uttar Pradesh, India.

Background: Epidermal growth factor receptor (EGFR) inhibitors are an extensively utilized class of chemotherapeutic agents which form an integral component of treatment in solid organ malignancies such as non-small-cell lung carcinoma, pancreatic carcinoma, colorectal carcinoma, and head and neck carcinoma. It has two subclasses: epidermal growth factor inhibitors (erlotinib) and monoclonal antibody (cetuximab). A wide array of cutaneous adverse effects has been attributed to this class of drugs, such as papulopustular eruptions, paronychia, xerosis, and changes in hair and nails. Read More

View Article and Full-Text PDF

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy.

Case Rep Dermatol 2019 Jan-Apr;11(1):101-107. Epub 2019 Apr 17.

Department of Dermatology, Liège University Hospital, CHU du Sart Tilman, Liège, Belgium.

BRAF inhibitors may present several cutaneous adverse effects, including actinic keratosis, squamous cell carcinoma, keratoacanthoma, rashes, increased photosensitivity, panniculitis, palmoplantar and capillary involvement, pruritus and xerosis as well as granulomatous reactions. A 30-year-old patient with multiple tattoos received dabrafenib and trametinib for metastatic melanoma. After 4 months, he developed an induration and thickening strictly limited to several tattoos. Read More

View Article and Full-Text PDF

Phenotypic analysis of atopic dermatitis in children aged 1-12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence.

J Eur Acad Dermatol Venereol 2019 Aug 17;33(8):1569-1576. Epub 2019 May 17.

Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Background: Atopic dermatitis (AD) is the most common skin disorder in infancy. However, the diagnosis and definite significance of infantile AD remains a debated issue.

Objective: To analyse the phenotypes of AD in infancy, to establish diagnostic criteria and to estimate the prevalence of this condition in China. Read More

View Article and Full-Text PDF

Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer.

Open Access Maced J Med Sci 2019 Mar 27;7(6):973-977. Epub 2019 Mar 27.

Section of Dermatology, University of Naples Federico II, Naples, Italy via Sergio Pansini 5, 80131 Naples, Italy.

Background: Tyrosine kinase inhibitors (TKIs) have been introduced for the treatment of lung cancer, improving progression-free survival, objective response rate, and quality of life. However, TKIs can lead to cutaneous toxicities, including papulopustular rash, xerosis, paronychia with/without pyogenic granulomas, scalp disorders, facial hair and/or eyelash growth.

Aim: In this study, we describe retrospectively all cases of mucocutaneous side effects in patients with lung cancer under TKIs referring to our outpatient for the skin care of oncological patients. Read More

View Article and Full-Text PDF

Xerosis in Patient with Vitamin A Deficiency - a Case Report.

Cesk Slov Oftalmol Spring 2018;73(5-6):222-224

Xerosis is a corneal and ocular surface disease caused by vitamin A deficiency. It is a rare disease in developed countries, but in third world countries it is a common cause of blindness. We describe a typical xerosis in patient with vitamin A deficiency and long-term malnutrition and alcoholism in our case. Read More

View Article and Full-Text PDF

A case report of toxic epidermal necrolysis associated with AZD-9291.

Drug Des Devel Ther 2018 11;12:2163-2167. Epub 2018 Jul 11.

Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, The People's Republic of China,

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a strain of small molecule inhibitors mainly used to treat the metastatic non-small cell lung cancer. Their predominant adverse effect is skin toxicity, usually manifested as acneiform rash, skin fissure, xerosis, and paronychia. Severe epidermal necrosis and exfoliation rarely occur. Read More

View Article and Full-Text PDF
December 2018